Nuvation Bio Inc. (NUVB)
NYSE: NUVB · Real-Time Price · USD
4.880
-0.070 (-1.41%)
At close: Oct 6, 2026, 4:00 PM EDT
4.950
+0.070 (1.43%)
After-hours: Oct 6, 2026, 7:41 PM EDT
Nuvation Bio Employees
Nuvation Bio had 305 employees as of June 30, 2026. The number of employees increased by 27 or 9.71% compared to the same quarter last year.
Employees
305
Change
27
Growth
9.71%
Revenue / Employee
$557,049
Profits / Employee
-$491,236
Market Cap
1.71B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 305 | 27 | 9.71% |
| Mar 31, 2026 | 307 | 34 | 12.45% |
| Dec 31, 2025 | 298 | 78 | 35.45% |
| Sep 30, 2025 | 291 | 88 | 43.35% |
| Jun 30, 2025 | 278 | 111 | 66.47% |
| Mar 31, 2025 | 273 | 114 | 71.70% |
| Dec 31, 2024 | 220 | 169 | 331.37% |
| Sep 30, 2024 | 203 | 150 | 283.02% |
| Jun 30, 2024 | 167 | 113 | 209.26% |
| Mar 31, 2024 | 159 | 106 | 200.00% |
| Dec 31, 2023 | 51 | -2 | -3.77% |
| Sep 30, 2023 | 53 | -1 | -1.85% |
| Jun 30, 2023 | 54 | -31 | -36.47% |
| Mar 31, 2023 | 53 | -15 | -22.06% |
| Dec 31, 2022 | 53 | -11 | -17.19% |
| Sep 30, 2022 | 54 | -4 | -6.90% |
| Jun 30, 2022 | 85 | 34 | 66.67% |
| Mar 31, 2022 | 68 | 30 | 78.95% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Sarepta Therapeutics | 835 |
| Agios Pharmaceuticals | 540 |
| Intellia Therapeutics | 377 |
| Ocular Therapeutix | 325 |
| Zymeworks | 231 |
| Stoke Therapeutics | 170 |
| Zenas BioPharma | 167 |
| Septerna | 123 |
NUVB News
- 6 days ago - Nuvation Bio initiated with a Buy at Citi - TheFly
- 19 days ago - Nuvation Bio announces FDA approval of sNDA for Ibtrozi - TheFly
- 19 days ago - Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in TKI-Naïve Advanced ROS1-Positive Non-Small Cell Lung Cancer - PRNewsWire
- 21 days ago - Nuvation Bio’s Ibtrozi shows durable efficacy in NSCLC studies - TheFly
- 21 days ago - Nuvation Bio Announces New Analyses Reinforcing the Durable, Consistent Efficacy of IBTROZI® (taletrectinib) Across Key Patient Subgroups in Advanced ROS1+ NSCLC at 2026 World Conference on Lung Cancer - PRNewsWire
- 26 days ago - Nuvation Bio Transcript: Cantor Global Healthcare Conference - Transcripts
- 27 days ago - Nuvation Bio Transcript: Citigroup’s Biopharma Back to School Summit 2026 - Transcripts
- 4 weeks ago - Nuvation Bio to Participate in Upcoming Investor Conferences - PRNewsWire